{"id":54526,"date":"2026-04-29T02:51:00","date_gmt":"2026-04-28T19:51:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=54526"},"modified":"2026-04-29T02:51:00","modified_gmt":"2026-04-28T19:51:00","slug":"piramal-pharma-limited-announces-results-for-q4-and-full-year-fy26","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=54526","title":{"rendered":"Piramal Pharma Limited Announces Results for Q4 and Full-year FY26"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

MUMBAI, India<\/span>, April 29, 2026 \/PRNewswire\/ — Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Fourth Quarter (Q4) and Full-year ended 31st<\/sup> March 2026.<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Consolidated Financial Highlights<\/b><\/span><\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

(in \u20b9 Crores or as stated)<\/i><\/b><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Particulars<\/b><\/span><\/p>\n<\/td>\n

\n

Q4FY26<\/b><\/span><\/p>\n<\/td>\n

\n

Q4FY25<\/b><\/span><\/p>\n<\/td>\n

\n

YoY %<\/b><\/span><\/p>\n<\/td>\n

\n

FY26<\/b><\/span><\/p>\n<\/td>\n

\n

FY25<\/b><\/span><\/p>\n<\/td>\n

\n

YoY %<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Revenue from Operations<\/b><\/span><\/p>\n<\/td>\n

\n

2,752<\/b><\/span><\/p>\n<\/td>\n

\n

2,754<\/b><\/span><\/p>\n<\/td>\n

\n

(0)\u00a0%<\/b><\/span><\/p>\n<\/td>\n

\n

8,869<\/b><\/span><\/p>\n<\/td>\n

\n

9,151<\/b><\/span><\/p>\n<\/td>\n

\n

(3)\u00a0%<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u00a0\u00a0 CDMO<\/i><\/span><\/p>\n<\/td>\n

\n

1,708<\/span><\/p>\n<\/td>\n

\n

1,788<\/span><\/p>\n<\/td>\n

\n

(4)\u00a0%<\/span><\/p>\n<\/td>\n

\n

4,915<\/span><\/p>\n<\/td>\n

\n

5,447<\/span><\/p>\n<\/td>\n

\n

(10)\u00a0%<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u00a0\u00a0 CHG<\/i><\/span><\/p>\n<\/td>\n

\n

755<\/span><\/p>\n<\/td>\n

\n

705<\/span><\/p>\n<\/td>\n

\n

7\u00a0%<\/span><\/p>\n<\/td>\n

\n

2,703<\/span><\/p>\n<\/td>\n

\n

2,633<\/span><\/p>\n<\/td>\n

\n

3\u00a0%<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u00a0\u00a0 PCH<\/i><\/span><\/p>\n<\/td>\n

\n

320<\/span><\/p>\n<\/td>\n

\n

274<\/span><\/p>\n<\/td>\n

\n

17\u00a0%<\/span><\/p>\n<\/td>\n

\n

1,274<\/span><\/p>\n<\/td>\n

\n

1,093<\/span><\/p>\n<\/td>\n

\n

17\u00a0%<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

EBITDA<\/b><\/span><\/p>\n<\/td>\n

\n

507<\/b><\/span><\/p>\n<\/td>\n

\n

603<\/b><\/span><\/p>\n<\/td>\n

\n

(16)\u00a0%<\/b><\/span><\/p>\n<\/td>\n

\n

1,135<\/b><\/span><\/p>\n<\/td>\n

\n

1,580<\/b><\/span><\/p>\n<\/td>\n

\n

(28)\u00a0%<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

EBITDA Margin <\/b><\/span><\/p>\n<\/td>\n

\n

18\u00a0%<\/b><\/span><\/p>\n<\/td>\n

\n

22\u00a0%<\/b><\/span><\/p>\n<\/td>\n

<\/td>\n\n

13\u00a0%<\/b><\/span><\/p>\n<\/td>\n

\n

17\u00a0%<\/b><\/span><\/p>\n<\/td>\n

<\/td>\n<\/tr>\n
\n

PAT Before Expectational Item<\/b><\/span><\/p>\n<\/td>\n

\n

167<\/b><\/span><\/p>\n<\/td>\n

\n

154<\/b><\/span><\/p>\n<\/td>\n

\n

9\u00a0%<\/b><\/span><\/p>\n<\/td>\n

\n

(130)<\/b><\/span><\/p>\n<\/td>\n

\n

91<\/b><\/span><\/p>\n<\/td>\n

\n

NM<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Exceptional Item1<\/sup><\/span><\/p>\n<\/td>\n

\n

(176)<\/span><\/p>\n<\/td>\n

\n

–<\/span><\/p>\n<\/td>\n

\n

NM<\/span><\/p>\n<\/td>\n

\n

(196)<\/span><\/p>\n<\/td>\n

\n

–<\/span><\/p>\n<\/td>\n

\n

NM<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

PAT After Expectational Item<\/b><\/span><\/p>\n<\/td>\n

\n

(9)<\/b><\/span><\/p>\n<\/td>\n

\n

154<\/b><\/span><\/p>\n<\/td>\n

\n

NM<\/b><\/span><\/p>\n<\/td>\n

\n

(326)<\/b><\/span><\/p>\n<\/td>\n

\n

91<\/b><\/span><\/p>\n<\/td>\n

\n

NM<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

1. During the quarter, the management has recognized an impairment loss of \u20b9. 176Cr in relation to intangible assets under development. Based on a reassessment incorporating changes in market conditions and updated commercial viability estimates, management concluded that the probable future economic benefits from the asset are no longer expected to be adequate to justify further capital deployment.<\/i>\u00a0 Accordingly, the carrying amount has been written down in full.<\/i><\/p>\n

Key Highlights<\/b><\/p>\n